Article
Gastroenterology & Hepatology
Ondrej Fabian, Adam Klocperk, Tereza Lerchova, Pavla Jencova, Lucie Stolova, Marie Belhajova, Dagmar Voriskova, Denis Kazeka, Ales Vicha, Ondrej Hradsky, Jiri Bronsky
Summary: This study found that sCD30 levels were associated with disease activity in patients with UC and CD, but were not useful in distinguishing between the two diseases. The immune response of T lymphocyte subsets varied in different parts of the intestine in UC patients and was also affected by anti-TNF treatment and patient age.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Mai Yamamoto, Meera Shanmuganathan, Lara Hart, Nikhil Pai, Philip Britz-McKibbin
Summary: Rates of pediatric Crohn's disease (CD) and ulcerative colitis (UC) are increasing globally. Differentiation based on urinary metabolic signatures can effectively distinguish between CD and UC, which is important for the diagnosis and early management of IBD.
Article
Radiology, Nuclear Medicine & Medical Imaging
Yunxi Zheng, Shouxin Gu, Jingyao Ruan, Xiaofang Yi, Congjian Xu
Summary: This study demonstrates the clinical significance of MRI features in diagnosing bowel endometriosis (BE) pre-operatively. Patients with deep endometriosis and a rectal wall thickness exceeding 6.0 mm have a higher probability of BE.
EUROPEAN RADIOLOGY
(2023)
Review
Gastroenterology & Hepatology
Olga Maria Nardone, Rosanna Cannatelli, Subrata Ghosh, Marietta Iacucci
Summary: Endoscopic remission is considered the ultimate long-term goal for treating inflammatory bowel disease. Advances in endoscopic techniques, such as virtual electronic chromoendoscopy, endocytoscope, and confocal laser endomicroscopy, provide more accurate assessments of the intestinal mucosa. Artificial Intelligence (AI) shows promise in revolutionizing IBD diagnosis and management. These new endoscopic tools, combined with AI, offer incredible opportunities for precision medicine in patients with IBD.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2022)
Article
Pharmacology & Pharmacy
Wilbert Bouwman, Wim Verhaegh, Anja van de Stolpe
Summary: The study used signal transduction pathway technology to quantify the activity of various pathways in colon mucosa samples of ulcerative colitis (UC) and Crohn's disease (CD) patients, and found that certain pathways were abnormally active and associated with resistance to anti-TNF alpha treatment. Abnormal activity decreased with successful treatment. Measuring mucosal STP activity can improve the diagnosis of inflammatory bowel disease and predict resistance to anti-TNF alpha treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Hua Luo, Guiqing Cao, Chun Luo, Dechao Tan, Chi Teng Vong, Yinyue Xu, Sicen Wang, Haitao Lu, Yitao Wang, Wanghui Jing
Summary: Inflammatory bowel disease (IBD) is a group of diseases characterized by chronic intestinal inflammation, with multiple factors involved in its pathogenesis. Currently, drug therapies are the main treatment for IBD, but they often have side effects and limited efficacy. Therefore, advanced drug delivery systems are needed for targeted treatment of the inflammatory sites.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Multidisciplinary Sciences
Chengxin Shi, Jianati Dawulieti, Feiyu Shi, Chao Yang, Qian Qin, Tongfei Shi, Lizhao Wang, Hanze Hu, Madi Sun, Li Ren, Fangman Chen, Yawei Zhao, Feng Liu, Mingqiang Li, Lijun Mu, Dan Liu, Dan Shao, Kam W. Leong, Junjun She
Summary: A new nanomedicine strategy has been developed for the treatment of inflammatory bowel disease (IBD) by scavenging proinflammatory cell-free DNA and reactive oxygen species, with minimal side effects.
Article
Microbiology
Christine Olbjorn, Milada Cvancarova Smastuen, Aina Elisabeth Fossum Moen
Summary: This study explored the fecal microbiota in pediatric patients with treatment-naive IBD and found that the abundance and species of bacteria differed between IBD patients and healthy children. Based on the abundance of bacterial species, diagnostic, phenotype, and prognostic indexes were constructed, which can aid in diagnosing and treating IBD.
Article
Gastroenterology & Hepatology
R. Gacesa, A. Vich Vila, V. Collij, Z. Mujagic, A. Kurilshikov, M. D. Voskuil, E. A. M. Festen, C. Wijmenga, D. M. A. E. Jonkers, G. Dijkstra, J. Fu, A. Zhernakova, F. Imhann, R. K. Weersma
Summary: This study aimed to develop a noninvasive fecal test to distinguish between IBD and IBS and reduce the use of endoscopies. Results show that fecal HBD2 has high sensitivity and specificity for differentiating between IBD and IBS, while combining microbiome data with other biomarkers has the potential to improve predictive power. HBD2, in combination with FCal and potentially gut microbiome data, was found to be a novel biomarker for IBD in patients with gastrointestinal complaints.
Article
Microbiology
Christopher H. Arehart, John D. Sterrett, Rosanna L. Garris, Ruth E. Quispe-Pilco, Christopher R. Gignoux, Luke M. Evans, Maggie A. Stanislawski
Summary: Inflammatory bowel disease (IBD) is a complex condition with disrupted colonic ecosystem. A framework for multi-omic data analysis was used to study the gut ecosystem in IBD. Metabolomics and viromics were found to be more predictive than metagenomics or metatranscriptomics, and combining all four scores improved disease diagnosis prediction.
Article
Gastroenterology & Hepatology
Nikolas Plevris, Charlie W. Lees
Summary: Inflammatory bowel disease is a progressive and debilitating condition, emphasizing the importance of early and effective treatment for improving patient outcomes. Proactive monitoring is crucial to ensuring treatment strategies are working, highlighting the need for an optimal treat-to-target monitoring strategy during key phases of the disease. The advent of new technology may enhance monitoring capabilities and shape future monitoring strategies for inflammatory bowel diseases.
Article
Engineering, Biomedical
Niranjan G. Kotla, Rajbir Singh, Becca Baby, Swetha Rasala, Jawad Rasool, Sean O. Hynes, Darrell Martin, Laurence J. Egan, Praveen K. Vemula, Venkatakrishna R. Jala, Yury Rochev, Abhay Pandit
Summary: Delivering drugs directly to inflamed intestinal sites to treat inflammatory bowel disease (IBD) is a challenge, but the development of targeted carrier systems such as IT-NCs shows promising therapeutic potential in improving treatment efficacy.
Article
Automation & Control Systems
Tangfan Xiahou, Zhiguo Zeng, Yu Liu
Summary: This article introduces a MoG-EHMM model that fuses expert knowledge and condition monitoring information for RUL prediction, demonstrating that the performance of RUL prediction can be substantially improved by incorporating expert knowledge with monitoring information.
IEEE TRANSACTIONS ON INDUSTRIAL INFORMATICS
(2021)
Review
Gastroenterology & Hepatology
Nghia H. Nguyen, Dominic Picetti, Parambir S. Dulai, Vipul Jairath, William J. Sandborn, Lucila Ohno-Machado, Peter L. Chen, Siddharth Singh
Summary: Studies comparing machine learning-based prediction models with traditional statistical models in inflammatory bowel diseases (IBD) found that machine learning models generally outperform traditional models in risk prediction, but often have a high risk of bias and require further validation and clinical applicability research.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Chemistry, Multidisciplinary
Dongtao Zhou, Yi Yin, Zhenxing Zhu, Yanfeng Gao, Jingjing Yang, Yongchun Pan, Yujun Song
Summary: Inflammatory bowel disease (IBD) is a chronic autoimmune disease with increasing incidence globally. This study presents an orally administered nanosensor that releases ultrasmall platinum nanoclusters (PtNCs) in IBD-related inflammatory environments, enabling non-invasive monitoring and diagnosis.